Lilly Alzheimer’s Drug Delayed on Need for Added Study

Eli Lilly & Co. said it will conduct an additional late-stage study of its experimental Alzheimer’s treatment, a move that could push the drug’s introduction back three years to 2016. The shares fell.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.